Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer

Bingyu Li,Kaifeng Jin,Zhaopei Liu,Xiaohe Su,Ziyue Xu,Ge Liu,Jingtong Xu,Hailong Liu,Yuan Chang,Yiwei Wang,Yu Zhu,Zewei Wang,Le Xu,Weijuan Zhang

DOI: https://doi.org/10.1007/s00262-024-03651-3

IF: 6.63

2024-03-03

Cancer Immunology Immunotherapy

Abstract:Luminal and Basal are the primary intrinsic subtypes of muscle-invasive bladder cancer (MIBC). The presence of CD8 + T cells infiltration holds significant immunological relevance, potentially influencing the efficacy of antitumor responses. This study aims to synergize the influence of molecular subtypes and CD8 + T cells infiltration in MIBC.

oncology,immunology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to predict the treatment response and survival of patients with muscle - invasive bladder cancer (MIBC) by integrating molecular subtypes and CD8+ T - cell infiltration. Specifically, the study aims to explore the following issues:

1. **The impact of combinations of different molecular subtypes and CD8+ T - cell infiltration levels on the prognosis of MIBC patients**:
- The researchers divided MIBC patients into four different subgroups: Luminal - CD8+Thigh, Luminal - CD8+Tlow, Basal - CD8+Thigh, and Basal - CD8+Tlow, in order to evaluate the differences in clinicopathological, genomic, and immunophenotypic characteristics among these subgroups.

2. **The responses of different subgroups to chemotherapy and immune checkpoint inhibitor treatment**:
- The researchers analyzed the survival rates and objective response rates (ORR) of patients in different subgroups after receiving platinum - based chemotherapy and PD - L1 blockade treatment, in order to determine which subgroups may benefit more from specific treatment methods.

3. **The role of immuno - molecular subtypes in guiding personalized treatment of MIBC**:
- The researchers hope to provide more precise treatment options for MIBC patients by integrating information on molecular subtypes and CD8+ T - cell infiltration, thereby improving the treatment effect.

### Main findings
- **The Basal - CD8+Tlow subgroup has the worst prognosis**: In multiple cohorts, patients in the Basal - CD8+Tlow subgroup had the shortest overall survival (OS), indicating that this subgroup has a poor prognosis.
- **The Basal - CD8+Thigh subgroup is sensitive to chemotherapy**: Patients in the Basal subgroup with high CD8+ T - cell infiltration had a better response to platinum - based chemotherapy, and their OS was significantly prolonged.
- **The Luminal - CD8+Thigh subgroup is effective for PD - L1 blockade treatment**: Patients in the Luminal subgroup with high CD8+ T - cell infiltration had a significantly prolonged OS and a higher objective response rate (ORR) after receiving PD - L1 blockade treatment.
- **The Luminal - CD8+Tlow subgroup is sensitive to targeted therapy**: Patients in the Luminal - CD8+Tlow subgroup are more likely to have FGFR3 mutations, which are associated with the effectiveness of targeted therapy.

### Conclusion
The study emphasizes the importance of immuno - molecular subtypes in the treatment of MIBC and provides a theoretical basis for future personalized treatment. By integrating information on molecular subtypes and CD8+ T - cell infiltration, treatment regimens can be more precisely selected for each patient, thereby improving the treatment effect.